Corporate and Pipeline developments
Pfizer’s (PFE) product developments include the details about product approvals and reviews granted. These developments include a few corporate developments and pipeline drugs.
In October 2017, Pfizer announced that the company is reviewing strategic alternatives, including full or partial separation through sale or a spin-off of its consumer healthcare business. The company specified that it may ultimately retain the business.
However, strategic alternatives will be considered, and the decision will be made in 2018. The company also clarified that it doesn’t plan to make any further statements until a decision has been made.
In October 2017, Pfizer announced the results of the phase-II clinical trials evaluating Lorlatinib (PF-06463922) for the treatment of patients with ALK+ and ROS1+ advanced non-small cell lung cancer. The results were presented at 18th World Conference of Lung Cancer from October 15, 2017, to October 18, 2017.
In October 2017, Pfizer initiated a phase-II clinical trial evaluating PF-06482077 vaccine, a multi-valent pneumococcal vaccine being evaluated to extend coverage to 20 serotypes.
In September 2017, Pfizer announced positive results from the phase-2b clinical trials evaluating PF-04956842, a JAK1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis. The results were presented at the 26th Congress of the European Academy of Dermatology and Venereology from September 13, 2017, to September 17, 2017.
Other big developments
In September 2017, Pfizer released positive data from Reflections B327-02, a phase-III study evaluating PF-05280014, a proposed trastuzumab biosimilar, for the treatment of HER2+ metastatic breast cancer. The data was released at European Society for Medical Oncology 2017 Congress.
In August 2017, Pfizer announced that the FDA accepted the Biologics License Application for PF-05280014. In July 2017, the European Medicines Agency validated the marketing authorization application for PF-05280014.